Skip to main content

Clinical trial CAEL101-301

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment- Naïve Patients with Mayo Stage IIIb AL Amyloidosis

Cancers
Organ Amyloidose
Trial status Trial closed for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Caelum Biosciences, Inc.
EudraCT Identifier 2019-004254-28
Inclusion criteria Stage Mayo IIIb
Last update